4
Changes in Ownership
Arcutis Biotherapeutics, Inc. Filed Acc 0001628280-26-070385
EVP, Chief Legal Officer sold 41,219 shares at an average $34.24 ($1,411,513)
- EVP, Chief Legal Officer acquired 40,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Matsuda Masaru EVP, Chief Legal Officer | 2026-11-02 | Sale 10b5-1 | −1,219 | $31.86 | $38,841 | 111,289 | D: show line 1 in the form |
| Matsuda Masaru EVP, Chief Legal Officer | 2026-11-04 | Option exercise 10b5-1 | +40,000 | $3.64 | $145,600 | 151,289 | D: show line 2 in the form |
| Matsuda Masaru EVP, Chief Legal Officer | 2026-11-04 | Sale 10b5-1 | −40,000 | $34.32 | $1,372,672 | 111,289 | D: show line 3 in the form |
| Open-market sales · 41,219 sh · avg $34.24 · $1,411,513 | |||||||
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Matsuda Masaru EVP, Chief Legal Officer | 2026-11-04 | Option exercise · Stock Option (right to buy) 10b5-1 | −40,000 | 136,000 | D: show line 4 in the form |
Loading xslF345X06/wk-form4_1793835532.xml…